Kaposi's sarcoma: DaunoXome approved.
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003630:Daunorubicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D017277:Drug Approval; D004337:Drug Carriers; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008081:Liposomes; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology; D014481:United States; D014486:United States Food and Drug Administration
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D008081:Liposomes; D004317:Doxorubicin; D003630:Daunorubicin